Assessment of the Risk of Hepatotoxicity with Kava Products

Front Cover
WHO Regional Office Europe, 2007 - Medical - 82 pages
There has been international concern over the association of kava products and serious hepatotoxicity. Regulatory action banning these products in Europe has been controversial. The objective of this report is to investigate the possibility of hepatotoxicity with kava. It contains a description of kava and provides safety information as well as information on regulatory issues, conclusions and recommendations by the Committee appointed to handle this enquiry.

What people are saying - Write a review

We haven't found any reviews in the usual places.

Common terms and phrases

Popular passages

Page 36 - Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain.
Page 28 - Anticonvulsive action of (+/— )-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites.
Page 43 - C, Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. Eur J Pharmacol 1992;215:265-9.
Page 37 - Walden J, von Wegerer J, Winter U, Berger M, Grunze H. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Progress Neuropsychopharmacol Biol Psychiat 1997:21:697-706.

About the author (2007)

World Health Organization is a Specialized Agency of the United Nations, charged to act as the world's directing and coordinating authority on questions of human health. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries, and monitoring and assessing health trends.

Bibliographic information